HC Wainwright Reaffirms Buy Rating for Regulus Therapeutics (NASDAQ:RGLS)

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report)'s stock had its "buy" rating reissued by analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $10.00 price target on the biopharmaceutical company's stock.

Regulus Therapeutics Price Performance

RGLS traded up $0.01 during midday trading on Friday, reaching $1.38. 163,319 shares of the company's stock traded hands, compared to its average volume of 519,136. Regulus Therapeutics has a 52 week low of $0.83 and a 52 week high of $3.00. The firm has a fifty day moving average of $1.28 and a two-hundred day moving average of $1.46. The stock has a market capitalization of $90.39 million, a price-to-earnings ratio of -1.29 and a beta of 1.42.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last announced its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.20) EPS for the quarter, meeting analysts' consensus estimates of ($0.20). During the same period in the prior year, the company posted ($0.40) EPS. Sell-side analysts forecast that Regulus Therapeutics will post -0.88 EPS for the current year.

Insider Activity

In other news, VP Christopher Ray Aker sold 38,547 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $1.26, for a total value of $48,569.22. Following the completion of the transaction, the vice president now owns 54,634 shares of the company's stock, valued at approximately $68,838.84. This represents a 41.37 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Joseph P. Hagan sold 115,290 shares of Regulus Therapeutics stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $145,265.40. Following the sale, the chief executive officer now owns 222,572 shares in the company, valued at $280,440.72. This represents a 34.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 223,998 shares of company stock valued at $282,237. Corporate insiders own 4.35% of the company's stock.

Remove Ads

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Jane Street Group LLC bought a new stake in Regulus Therapeutics during the third quarter worth about $46,000. PEAK6 LLC bought a new stake in shares of Regulus Therapeutics in the 4th quarter worth approximately $95,000. Velan Capital Investment Management LP purchased a new stake in shares of Regulus Therapeutics in the 4th quarter worth approximately $111,000. JPMorgan Chase & Co. increased its position in Regulus Therapeutics by 193.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company's stock valued at $124,000 after buying an additional 52,059 shares in the last quarter. Finally, Barclays PLC increased its position in Regulus Therapeutics by 285.2% during the 3rd quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company's stock valued at $132,000 after buying an additional 62,549 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.